XML 24 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT) - USD ($)
Total
Conversion Following Business Combination
Conversion Of Class C Into Class A Shares
Common Class A
Common Class C
Previously Reported
Total Shareholders' Equity (Deficit)
Total Shareholders' Equity (Deficit)
Conversion Following Business Combination
Total Shareholders' Equity (Deficit)
Conversion Of Class C Into Class A Shares
Total Shareholders' Equity (Deficit)
Previously Reported
Preferred Stock
Preferred Stock
Conversion Following Business Combination
Preferred Stock
Previously Reported
Preferred Stock
Revision of Prior Period, Adjustment
Common Stock
Common Stock
Conversion Following Business Combination
Common Stock
Common Class A
Common Stock
Common Class A
Conversion Following Business Combination
Common Stock
Common Class A
Conversion Of Class C Into Class A Shares
Common Stock
Common Class C
Common Stock
Common Class C
Conversion Following Business Combination
Common Stock
Common Class C
Conversion Of Class C Into Class A Shares
Common Stock
Previously Reported
Common Stock
Revision of Prior Period, Adjustment
Treasury Stock, Common
Treasury Stock, Common
Conversion Following Business Combination
Treasury Stock, Common
Previously Reported
Treasury Stock, Common
Revision of Prior Period, Adjustment
Additional Paid-In Capital
Additional Paid-In Capital
Conversion Following Business Combination
Additional Paid-In Capital
Conversion Of Class C Into Class A Shares
Additional Paid-In Capital
Previously Reported
Accumulated Deficit
Accumulated Deficit
Previously Reported
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income
Conversion Of Class C Into Class A Shares
Accumulated Other Comprehensive Income
Previously Reported
Noncontrolling Interests
Noncontrolling Interests
Conversion Of Class C Into Class A Shares
Preferred stock, beginning balance (in shares) at Dec. 31, 2021                     22,880,908   680,196 22,200,712                                                  
Equity, beginning balance at Dec. 31, 2021 $ (11,645,007)         $ (11,645,007) $ (11,645,007)     $ (11,645,007) $ 72,466   $ 72,466   $ 38,537               $ 38,537   $ (6,202)   $ (6,202)   $ 42,061,984     $ 42,061,984 $ (53,643,615) $ (53,643,615) $ (168,177)   $ (168,177)    
Common stock, beginning balance (in shares) at Dec. 31, 2021                             12,161,331               361,528 11,799,803                              
Held in Treasury, beginning balance (in shares) at Dec. 31, 2021                                                 (1,942,837)   (57,756) (1,885,081)                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                                              
Noncontrolling interests recognized on historical net assets of MoonLake AG in connection with the Business Combination 0           8,346,506       $ (23,939)       $ (12,730)                   $ 797       (14,551,870)       22,966,652   (32,404)     $ (8,346,506)  
Conversion and transfer of shares between classes (in shares)                       (22,880,908)     61,000 (12,161,331) 2,051,961 18,501,284 2,051,961 2,051,961 15,775,472 (2,051,961)       765,483                          
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares   $ 1,578 $ 0         $ 1,578 $ 3,536,045     $ (48,527)       $ (25,807)   $ 1,850 $ 205   $ 1,578 $ (205)       $ 1,614       $ 70,870 $ 3,520,306         $ 15,739     $ (3,536,045)
Issuance of Class A ordinary shares upon Business Combination (in shares)                                 18,424,355                                            
Issuance of Class A Ordinary Shares upon Business Combination 134,653,204           90,783,936                   $ 1,843                       90,782,093                 43,869,268  
Emission fees and capital tax payments on share issuance (56,240)           (40,078)                                           (40,078)                 (16,162)  
Share-based compensation granted under the equity incentive plan ESPP, ESOP, and reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan (in shares)                                                 1,177,354                            
Share-based compensation granted under the equity incentive plan ESPP, ESOP, reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan 9,658,568           7,352,777                                   $ 3,791       7,348,986                 2,305,791  
Net loss (64,506,051)           (49,973,249)                                                   (49,973,249)         (14,532,802)  
Other comprehensive income 660,646           535,788                                                       535,788     124,858  
Equity, end balance at Dec. 31, 2022 $ 68,766,698           48,898,296                   $ 3,898     $ 1,373                 129,192,291       (80,650,212)   350,946     19,868,402  
Common stock, ending balance (in shares) at Dec. 31, 2022       38,977,600 13,723,511                       38,977,600     13,723,511                                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                                              
Issuance of Class A ordinary shares upon Business Combination (in shares)       18,501,284 15,775,472                                                                    
Issuance of Class A Ordinary Shares, net of transaction costs (in shares)       11,700,000                                                                      
Common stock, ending balance (in shares) at Apr. 05, 2022 52,701,111                                                                            
Common stock, beginning balance (in shares) at Dec. 31, 2022       38,977,600 13,723,511                       38,977,600     13,723,511                                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                                              
Conversion and transfer of shares between classes (in shares)                             333,486   11,218,035     (11,218,035)                                      
Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares $ 0           52,989,048                   $ 1,122     $ (1,122)                 52,479,045           510,003     (52,989,048)  
Share-based compensation granted under the equity incentive plan ESPP, ESOP, reverse vesting of Restricted Founder Shares and 2022 MoonLake Immunotherapeutics Equity Incentive Plan 7,106,005           5,907,406                                           5,907,406                 1,198,599  
Net loss (44,079,117)           (36,007,260)                                                   (36,007,260)         (8,071,857)  
Other comprehensive income 1,993,522           1,495,537                                                       1,495,537     497,985  
Issuance of Class A Ordinary Shares, net of transaction costs (in shares)                             10,270,818   10,270,818                                            
Issuance of Class A Ordinary Shares, net of transaction costs (Note 12) 482,454,426           482,454,426                   $ 1,027                       482,453,399                    
Capital injection from MoonLake to MoonLake AG (Note 12) (2,750,515)           (60,060,626)                                           (60,061,761)           1,135     57,310,111  
Refund of stamp duty fees 0           (1,144)                                           (1,144)                 1,144  
Equity, end balance at Dec. 31, 2023 $ 513,491,019           $ 495,675,683                   $ 6,047     $ 251                 $ 609,969,236       $ (116,657,472)   $ 2,357,621     $ 17,815,336  
Common stock, ending balance (in shares) at Dec. 31, 2023       60,466,453 2,505,476                       60,466,453     2,505,476